NLRP3 and diabetes mellitus: On the basis of preceding awareness pertaining to antidiabetic agents used for managing Type 2 diabetes mellitus and utilizing the NLRP3 inflammasome suppressive effects of MCC950 (CRID3) in nanomolar concentrations, a fascinating assemblage of nine crossbreed compounds have been advanced [49].